← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Eptifibatide

FDA approved · Rx

Glycoprotein IIb/IIIa inhibitor

Also known as: Integrilin, Integrelin, Eptifibatida, epifibatide, epifibratide, eptifibatidum

Evidence score
91/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 35 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Eptifibatide is a synthetic cyclic heptapeptide, sold originally as Integrilin, that is given intravenously in hospital settings. It blocks the glycoprotein IIb/IIIa receptor on platelets, which prevents fibrinogen from linking platelets together and so reduces clot formation.

What the evidence shows

Automatic summaryHuman trials

It is FDA approved for patients with acute coronary syndrome and for those undergoing percutaneous coronary intervention, supported by large randomized trials and over 1,100 published papers. Bleeding is its main known risk, and its role has narrowed as newer antiplatelet drugs have become standard.

Key facts

Molecular formula
C35H49N11O9S2
Molecular weight
832 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

35registered studies
Phase 4most advanced phase
21completed (sample)
0recruiting (sample)

Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

Phase 2CompletedNCT00250991

Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG

UnknownNCT03383393

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

Phase 2CompletedNCT00317395

Multi-arm Optimization of Stroke Thrombolysis

Phase 3CompletedNCT03735979

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1,130papers referencing Eptifibatide

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

N Engl J Med1998

Targeting integrin pathways: mechanisms and advances in therapy.

Signal Transduct Target Ther2023

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

JAMA2003

Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.

Circulation2000

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.